CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with expectations of 15-20% revenue growth and stable margins. Product development and market expansion strategies are robust, with a focus on neurodiagnostics. The Q&A highlights investments in future growth, positive momentum in new segments, and strong gross margins. Despite higher OpEx due to litigation, the outlook remains optimistic. No major negative trends or uncertainties were identified, and the overall sentiment from analysts was positive, suggesting a likely stock price increase.
Key Financial Performance
Total Revenue $26.5 million in Q1 2026, a 29% increase year-over-year from $20.5 million in Q1 2025. The increase was primarily driven by increased adoption of the Ceribell System across new and existing accounts.
Product Revenue $20.2 million in Q1 2026, a 29% increase year-over-year from $15.6 million in Q1 2025. This growth was driven by increased adoption of the Ceribell System.
Subscription Revenue $6.3 million in Q1 2026, a 29% increase year-over-year from $4.9 million in Q1 2025. This growth was also attributed to increased adoption of the Ceribell System.
Gross Margin 87% in Q1 2026 compared to 88% in Q1 2025. The slight decrease was due to reliance on inventory acquired from China at an elevated tariff rate, which was nearly offset by cost reduction initiatives.
Operating Expenses $43.9 million in Q1 2026, a 36% increase year-over-year from $32.2 million in Q1 2025. The increase was due to investments in the commercial organization, a national sales meeting, and higher expenses related to ongoing IP litigation.
Net Loss $19.7 million in Q1 2026, compared to $12.8 million in Q1 2025. The increase in net loss was driven by higher operating expenses, including litigation and R&D costs.
Adjusted EBITDA Loss $11.2 million in Q1 2026, compared to $10.9 million in Q1 2025. This metric excludes noncash stock-based compensation and legal expenses associated with IP litigation.
Cash, Cash Equivalents, and Marketable Securities $141.2 million as of March 31, 2026. This reflects the company's strong balance sheet and confidence in achieving cash flow breakeven.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Neonate and Pediatric Products: Initiated full commercial launch following a successful pilot at 5 sites. These products aim to improve seizure management for vulnerable patients, with all pilot hospitals moving to full implementation.
Delirium Monitoring Solution: Activated the first site of the delirium pilot in April 2026. This is the first FDA-cleared diagnostic tool for delirium, targeting a $1 billion market. Full commercial launch expected in Q4 2026 or Q1 2027.
LVO Stroke Indication: Received Breakthrough Device Designation in January 2026. Clinical programs are progressing.
Hospital Account Expansion: Added 33 new hospital accounts in Q1 2026, reaching a total of 680 active accounts. Strong growth in VA system and pilot launched in U.S. military hospitals.
Market Opportunity: Estimated total addressable market in the U.S. increased to $3.5 billion, nearly double from the previous year.
Revenue Growth: Achieved $26.5 million in Q1 2026 revenue, a 29% year-over-year increase. Product revenue and subscription revenue both grew by 29%.
Gross Margin: Maintained an 87% gross margin in Q1 2026, with expectations to sustain high 80% margins throughout the year.
Operational Efficiencies: Shifted inventory sourcing to Vietnam to reduce tariff costs, expected to positively impact margins in the latter half of 2026.
EEG as a Vital Sign: Continued progress towards establishing EEG as a standard for neurological care, with advancements in seizure, delirium, and stroke monitoring solutions.
CMS NTAP Proposal: Received a supportive CMS proposed rule for a New Technology Add-on Payment for the delirium monitoring solution, potentially providing $2,171 per patient reimbursement starting October 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Costs: The company faced elevated tariff rates on inventory acquired from China, which impacted gross margins. Although cost reduction initiatives offset this expense, reliance on such inventory poses a risk until the transition to Vietnam-sourced inventory is complete.
IP Litigation Costs: Ongoing intellectual property litigation resulted in $5.6 million in expenses during Q1 2026, significantly higher than prior quarters. This reflects the unpredictable and potentially escalating costs of legal disputes.
Seasonal ICU Census Reduction: The company anticipates a sequential moderation in Q2 and Q3 volumes due to a reduction in ICU census during warmer months, which could impact revenue growth.
High Operating Expenses: Total operating expenses increased by 36% year-over-year, driven by investments in sales, marketing, and R&D, as well as litigation costs. This rise in expenses could pressure profitability.
Dependence on New Product Launches: The success of new product launches, such as the delirium monitoring solution, is critical to future growth. Delays or challenges in adoption could hinder revenue and market expansion.
Regulatory and Reimbursement Risks: The company is awaiting a final CMS rule for NTAP reimbursement for its delirium monitoring solution. A negative outcome could impact the adoption and financial viability of this product.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Gross Margin: Expected to maintain gross margin in the high 80% range throughout 2026.
Account Growth: Confident in increasing the number of new account additions in 2026 above 2025 levels, supported by expanded sales organization, VA system penetration, and a pilot at U.S. military hospitals.
Productivity of Sales Team: Expect further step-up in productivity of new hires throughout 2026, with additional acceleration in 2027.
Delirium Monitoring Solution: On track for a full commercial launch in Q4 2026 or Q1 2027. CMS proposed rule for NTAP reimbursement of up to $2,171 per patient, with a final rule expected in August 2026 and potential effectiveness by October 1, 2026.
Revenue Guidance: Full year 2026 total revenue expected to range from $112 million to $116 million, representing annual growth of 26% to 30% over 2025.
LVO Stroke Indication: Continuing clinical programs for LVO stroke indication after receiving Breakthrough Device Designation in January 2026.
Market Expansion: Total addressable market estimated at $3.5 billion in the U.S., nearly double from a year ago.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you explain the decision to raise the guidance after Q1 results and your confidence in the outlook for the year?
A:The company raised guidance due to strong performance in account acquisition and same-store growth. They had their largest quarter of net new adds since becoming a public company and record usage per account, which forms the foundation of their confidence.
Q:Why was OpEx higher than expected in Q1, and does this change your outlook for the full year?
A:OpEx was elevated due to increased investments in sales, marketing, and R&D, as well as $5.6 million in litigation expenses. These are considered investments for future growth, and the litigation expenses are expected to moderate later in the year.
Q:What are the early feedback and utilization trends for pediatric and neonate segments, and how meaningful are they for this year's guidance?
A:The company sees positive momentum with neonate pilot sites moving to full execution and strong interest in neonate expansion. However, the revenue impact is expected to be more meaningful in 2027 and beyond, with some impact in 2026.
Q:What drove the strong gross margin in Q1 and the guidance for the year?
A:The strong gross margin was driven by cost mitigation investments made last year, including manufacturing in Vietnam. None of the margin improvement was due to tariff refunds, which have not yet been reflected in financial statements.
Q:What factors led to the conversion of neonate pilot accounts to full launch?
A:Neonate pilot accounts converted to full launch due to strong safety validation, ease of use, accuracy of Clarity, and health economic benefits like reduced patient transfers and associated reimbursements.
Q:What are the key drivers for the record account adds in Q1, and how sustainable are they?
A:The record account adds were driven by a focus on regional hospital systems, coordination across teams, and a more sophisticated management approach. Early indicators suggest optimism for sustained growth.
Q:How is the systematic department expansion initiative impacting utilization at same-store accounts?
A:The initiative focuses on departmental expansion, provider engagement, and verticalization across patient populations. Strong execution and investments in leadership and CAM teams have contributed to improved utilization.
Q:How do you expect the delirium and seizure indications to interact synergistically?
A:Delirium and seizure indications are clinically intertwined, with overlapping patient populations and treatment challenges. The company expects the delirium launch to drive deeper penetration for seizure indications by addressing these overlaps.
Q:Will the delirium pilot lead to incremental revenue or primarily support market expansion?
A:The delirium pilot could drive both incremental revenue and market expansion. Pricing strategies and patient expansion impacts are being studied during the pilot phase.
Q:Are you comfortable with the consensus estimate of $27.2 million for Q2, given the seasonality commentary?
A:The company did not comment specifically on the Q2 consensus but emphasized confidence in full-year guidance. They reminded that Q2 and Q3 are typically lower due to seasonality.
Q:How long does it take for a sales representative to reach peak productivity?
A:It generally takes about a year for a sales representative to generate their first new account, with productivity increasing as they gain experience. The company is optimistic about continued growth as more reps reach this stage.
Q:Is there seasonality in account adds similar to utilization trends?
A:There is no specific seasonality in account adds, but there may be quarter-to-quarter lumpiness. The overall trend is upward.
Q:What is the opportunity and TAM for military hospitals and the VA network?
A:The military hospital network includes about 30 hospitals, while the VA network has 170 hospitals. Both present meaningful opportunities, leveraging cybersecurity success and addressing unmet clinical needs.
Q:How does the LVO monitoring algorithm complement CT and MRI imaging tools?
A:The LVO monitoring algorithm provides continuous monitoring to triage and detect LVO faster, potentially triggering workflows for CT or MRI confirmation and reducing detection delays.
Q:How does utilization in VA hospitals compare to non-VA hospitals?
A:The company does not disclose system-level utilization data, including comparisons between VA and non-VA hospitals.
Q:Is the $5.6 million litigation expense in Q1 a peak spend, and how does it compare to previous quarters?
A:The $5.6 million litigation expense in Q1 is higher than the $1-2 million per quarter seen previously. Q2 is also expected to be elevated, with moderation expected later in the year.
Q:Review of Unclear Management Responses
A:The company avoided providing specific guidance on Q2 consensus estimates, stating only that they are confident in full-year guidance and reminding about seasonality. Additionally, they did not disclose system-level utilization data for VA versus non-VA hospitals or make a decision on pricing strategies for the delirium pilot.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ER
ICU
VA
account
activity
addition
base
boy
cash
delirium monitoring
delirium solution
expansion
expense IP
goal standard
headband
hospital
increase
interest
launch product
litigation
loss
margin
market
momentum
monitoring solution
opportunity
patient
pilot
platform
rule
sale
seizure
share
site
standard care
system
technology
today CeriBell
utilization
world
CBLL Transcript
CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary indicates strong financial performance with expectations of 15-20% revenue growth and stable margins. Product development and market expansion strategies are robust, with a focus on neurodiagnostics. The Q&A highlights investments in future growth, positive momentum in new segments, and strong gross margins. Despite higher OpEx due to litigation, the outlook remains optimistic. No major negative trends or uncertainties were identified, and the overall sentiment from analysts was positive, suggesting a likely stock price increase.
CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call summary shows strong financial performance with a 15% revenue increase and improved gross margins. Strategic initiatives and revenue guidance are optimistic, with a raised full-year guidance and market expansion plans. Although there are no shareholder return plans mentioned, the positive financial metrics and growth strategies outweigh potential risks, leading to an overall positive sentiment.
Caris Life Sciences, Inc. (CAI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
